THE GREAT BIOTECH HEIST IS UNDERWAY. In a shocking corporate power grab that will CONSOLIDATE the fate of millions of patients into the hands of a single pharmaceutical GOLIATH, Europe’s top-performing stock, Abivax, is being PRIMED for a $23 BILLION takeover. This isn’t just business—it’s a DANGEROUS monopolization of a revolutionary treatment that promises hope for ulcerative colitis and Crohn’s disease sufferers worldwide.
Shares of this French biotech EXPLODED by a mind-bending 1,681% last year, a rally fueled by trial results so positive they sent Wall Street into a frenzy. But now, the VERY PATIENTS who depend on this breakthrough drug, obefazimod, are about to become pawns in a high-stakes game of profit and power. The predator? Rumor points directly to Eli Lilly, the world’s most valuable pharma titan, a company already under fire for its EYE-WATERING drug prices. This acquisition isn’t about innovation—it’s about ELIMINATING competition and CONTROLLING the market.
Analysts coldly admit the deal is a matter of “when, not if,” exposing a brutal truth: groundbreaking science no longer belongs to the pioneers. It is DEVOURED by mega-corporations that prioritize shareholder returns over patient access. The company’s own CEO, a serial dealmaker, is already in “conversation with Big Pharma,” a chilling euphemism for auctioning off a medical miracle to the highest bidder.
This is the FINAL STAGE of a sick system where life-saving treatments are not discovered, but CAPTURED. As these faceless giants hoard the world’s medical future, one terrifying question remains: who will control your health when every cure has a single corporate owner?
Author: Kayitsi.com
